| Clinical data | |
|---|---|
| Other names | TAK-360; TAK360 |
| Routes of administration | Oral |
| Drug class | Orexin OX2 receptor antagonist; Wakefulness-promoting agent |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H12F6N4O4S |
| Molar mass | 518.39 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Balumorexton (INN; likely developmental code name TAK-360) is a selective orexin OX2 receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia. It is taken orally. The drug is under development by Takeda. As of June 2025, it is in phase 2 clinical trials for both narcolepsy and idiopathic hypersomnia.